论文部分内容阅读
为了探讨质子泵抑制剂预防及抑制化疗所引起的化学性胃炎的有效性 ,随机对照研究了不同治疗方法 ,预防基于多柔比星、氮烯咪胺、铂类、伊立替康和 5 -氟尿嘧啶所组成的化疗方案所致的胃炎的疗效 ,研究组采用质子泵抑制剂、安定和 5 HT3 受体拮抗剂预防胃炎和呕吐方法 ,对照组使用常规传统的地塞米松加 5 HT3 受体拮抗剂 ,进行跟踪观察、疗效比较 ,并从不良反应、耐受性及安全性等方面加以分析比较。研究组胃炎发生率 0 ( 0 /11) ,对照组为 72 .73 % ( 8/11) ,P =0 0 0 1;化疗后完全无上消化道症状 /体征者 ,研究组 75 0 0 % ( 3 3 /4 4) ,对照组 5 2 2 8% ( 2 4/4 6) ,P =0 0 2 5 ;化疗后 7d无症状 /体征者 ,研究组 10 0 % ( 4 4/4 4) ,对照组 76 0 9% ( 3 5 /4 6) ,P =0 0 0 1。初步研究结果提示 ,质子泵抑制剂对化疗过程中所引起的化学性胃炎有明显的预防及抑制作用 ,而且有效率高、不良反应小、安全性好 ,患者有良好的耐受性。
In order to investigate the effectiveness of proton pump inhibitors in the prevention and treatment of chemical gastritis caused by chemotherapy, different treatments were randomized and controlled to prevent the effects of doxorubicin, dacarbazine, platinum, irinotecan and 5 - fluorouracil The composition of the chemotherapy-induced gastritis curative effect, the study group using proton pump inhibitor, diazepam and 5 HT3 receptor antagonist to prevent gastritis and vomiting, the control group using conventional conventional dexamethasone plus 5 HT3 receptor antagonist , Follow-up observation, efficacy comparison, and from the side effects, tolerance and safety analysis and comparison. In the study group, the incidence of gastritis was 0 (0/11) in the control group, 72.73% (8/11) in the control group, P = 0 0 01. There was no symptoms or signs of upper gastrointestinal tract after chemotherapy in the study group, 75 0% (3 4/4 4), control group 52.8% (2 4/4 6), P 0 025; asymptomatic / symptom 7 days after chemotherapy, the study group 10 0% (4 4/4 4 ), Control group 76 0 9% (3 5/46), P = 0 0 0 1. Preliminary results suggest that proton pump inhibitors on the chemical treatment of chemical gastritis caused by significant preventive and inhibitory effect, and high efficiency, adverse reactions, safety, good patient tolerance.